

# 2023 Publications

Spherix Global Insights

[info@spherixglobalinsights.com](mailto:info@spherixglobalinsights.com)

484.879.4284



## MARKET DYNAMIX

**Market Dynamix™** is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years, highlighting market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

**Methodology:** Insights are based on analyses of quantitative data collected from an online survey of specialists, patients, and leading KOLs recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents and select KOLs.

### Sample Size & Frequency

- US: annual report (n=100 physicians)
- EU5: annual report (n=200 physicians)
- Qualitative interviews (n=6-8 physicians, n=1-2 KOLs)

## LAUNCH DYNAMIX

**Launch Dynamix™** is an independent service providing a monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into patient types initiated, brand perceptions, promotional activity, and drivers and barriers to uptake.

**Methodology:** Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.

### Sample Size & Frequency

- Monthly KPI dashboard (n=75 physicians)
- Quarterly report (n=75 physicians)
- Quarterly qualitative interviews (n=8 physicians)



## REALTIME DYNAMIX

**RealTime Dynamix™** is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.

**Methodology:** Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

### Sample Size & Frequency

- US: quarterly report (n=100 respondents)
- EU5: semiannual report (n=250 respondents)
- Canada: semiannual report (n=50 respondents)

## REALWORLD DYNAMIX

**RealWorld Dynamix™** is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

**Methodology:** Insights are based on patient level data gathered through collaboration with specialty physicians who provide details on clinical and non-clinical patient demographics, along with their rationale for treatment choices.

### Sample Size & Frequency

- US: annual patient chart audit (n=1,000 charts, n=200 physicians)
- EU5: annual patient chart audit (n=1,250 charts, n=250 physicians)



## SPECIAL TOPIX

**Special Topix™** is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

**Methodology:** Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

### Sample Size & Frequency

- Report cadence and deliverable depend upon current event/topic being evaluated



## Atopic Dermatitis

### REALTIME DYNAMIX

- *Atopic Dermatitis (US)*
- *Atopic Dermatitis (EU5)*

### LAUNCH DYNAMIX

- *Adbry (LEO) in Atopic Dermatitis (US)*
- *Cibinqo (Pfizer) in Atopic Dermatitis (US)*
- *Opzelura (Incyte) in Atopic Dermatitis (US)*
- *Rinvoq (AbbVie) in Atopic Dermatitis (US)*
- *Etrasimod (Pfizer) in Atopic Dermatitis (US)\**
- *Lebrikizumab (Eli Lilly) in Atopic Dermatitis (US)\**
- *Vtama (Dermavant) in Atopic Dermatitis (US)\**
- *Zoryve (Arcutis) in Atopic Dermatitis (US)\**

### REALWORLD DYNAMIX

- *Advanced Systemics in Atopic Dermatitis (US)*
- *Advanced Systemics in Atopic Dermatitis (EU5)*

---

## Plaque Psoriasis

### REALTIME DYNAMIX

- *Plaque Psoriasis (US)*
- *Plaque Psoriasis (EU5)*

### LAUNCH DYNAMIX

- *Sotyktu (BMS) in Plaque Psoriasis (US)*
- *Vtama (Dermavant) in Plaque Psoriasis (US)*
- *Zoryve (Arcutis) in Plaque Psoriasis (US)*
- *Bimzelx (UCB) in Plaque Psoriasis (US)*
- *Sonelokimab (MoonLake/Merck) in Plaque Psoriasis (US)\**

### REALWORLD DYNAMIX

- *Biologic/Small Molecule Switching in Plaque Psoriasis (US)*

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Emerging Dermatology

### MARKET DYNAMIX

- Alopecia Areata (US)
- Alopecia Areata (EU5)
- Hidradenitis Suppurativa (US)
- Hidradenitis Suppurativa (EU5)
- Prurigo Nodularis (US)
- Vitiligo (US)

### LAUNCH DYNAMIX

- Dupixent (Sanofi/Regeneron) in Prurigo Nodularis (US)
- Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria (US)\*
- Olumiant (Eli Lilly) in Alopecia Areata (US)
- Opzelura (Incyte) in Vitiligo (US)
- Cosentyx (Novartis) in Hidradenitis Suppurativa (US)\*
- Deuruxolitinib (Concert) in Alopecia Areata (US)\*
- Nemoлизumab (Galderma) in Prurigo Nodularis (US)\*
- Ritlecitinib (Pfizer) in Alopecia Areata (US)\*

### REALWORLD DYNAMIX

- Alopecia Areata (US)

### SPECIAL TOPIX

- Biosimilars Today and Tomorrow - Dermatology (US)
- Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Inflammatory Bowel Disease

### REALTIME DYNAMIX

- Crohn's Disease (US)
- Crohn's Disease (EU5)
- Ulcerative Colitis (US)
- Ulcerative Colitis (EU5)

### LAUNCH DYNAMIX

- Rinvoq (AbbVie) in Ulcerative Colitis (US)
- Skyrizi (AbbVie) in Crohn's Disease (US)
- Velsipity (Arena) in Ulcerative Colitis (US)
- Mirikizumab (Eli Lilly) in Ulcerative Colitis (US)\*
- Rinvoq (AbbVie) in Crohn's Disease (US)\*

### REALWORLD DYNAMIX

- Biologic/Small Molecule New Starts in IBD (US)
- Biologic/Small Molecule Switching in IBD (US)
- Biologic/Small Molecule Switching in IBD (EU5)

---

## Eosinophilic Esophagitis

### MARKET DYNAMIX

- Eosinophilic Esophagitis (US)

### LAUNCH DYNAMIX

- Dupixent (Sanofi/Regeneron) in Eosinophilic Esophagitis (US)
- APT-1011 (Ellodi) in Eosinophilic Esophagitis (US)\*

### REALWORLD DYNAMIX

- Treatment New Starts and Switching in Eosinophilic Esophagitis (US)

---

## Emerging Gastroenterology

### MARKET DYNAMIX

- Clostridioides Difficile (US)
- Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (US)

### LAUNCH DYNAMIX

- Ridinilazole (Summit) in Clostridium Difficile Infection (US)\*
- SER109 (Seres) in Clostridium Difficile Infection (US)\*
- Lanifibranor (Inventiva) in Non-Alcoholic Fatty Liver Disease\*
- Resmitrom (Madrigal) in Non-Alcoholic Fatty Liver Disease\*
- Reboyta (Ferring) in Clostridium Difficile Infection (US)\*

### SPECIAL TOPIX

- Biosimilars Today and Tomorrow - Gastroenterology (US)
- Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Kidney Disease

### REALTIME DYNAMIX

- *Chronic Kidney Disease & Diabetic Kidney Disease (US)*
- *Hyperkalemia (US)*

### LAUNCH DYNAMIX

- *Kerendia (Bayer) in Diabetic Kidney Disease (US)*
- *Korsuva (CSL Vifor) in CKD-Associated Pruritus (US)*

### REALWORLD DYNAMIX

- *Chronic Kidney Disease, Non-Dialysis (US)*
- *Chronic Kidney Disease, Non-Dialysis (EU5)*
- *Dialysis (US)*
- *Dialysis (EU5)*

---

## Renal Anemia

### REALTIME DYNAMIX

- *Renal Anemia (US)*
- *Renal Anemia (EU5)*

### REALWORLD DYNAMIX

- *Dialysis - Renal Anemia (US)*

### LAUNCH DYNAMIX

- *Jesduvroq (GSK) in Renal Anemia (US)*

---

## Bone and Mineral Metabolism

### REALTIME DYNAMIX

- *Bone and Mineral Metabolism (US)*
- *Bone and Mineral Metabolism Renal Dietitians (US)*

### REALWORLD DYNAMIX

- *Bone and Mineral Metabolism (US)*

### LAUNCH DYNAMIX

- *Xphozah (Ardelyx) in Hyperphosphatemia (US)*
- *Xphozah (Ardelyx) in Hyperphosphatemia - Renal Dietitian Perspectives (US)*





## Glomerular Diseases

### MARKET DYNAMIX

- *Focal Segmental Glomerulosclerosis (US)*
- *IgA Nephropathy (US)*
- *IgA Nephropathy (EU5)*
- *IgA Nephropathy (Japan)*
- *Rare Glomerular Diseases (EU5)*

### LAUNCH DYNAMIX

- *Tarpeyo (Calliditas) in IgA Nephropathy (US)*
- *Filspari (Travere) in IgA Nephropathy (US)\**

### REALWORLD DYNAMIX

- *Complement 3 Glomerulopathy (EU5)*
- *Focal Segmental Glomerulosclerosis (US)*
- *IgA Nephropathy (US)*
- *IgA Nephropathy (EU5)*
- *IgA Nephropathy (China)*
- *IgA Nephropathy (Japan)*

---

## Lupus Nephritis

### REALTIME DYNAMIX

- *Lupus Nephritis (US)*

### REALWORLD DYNAMIX

- *Lupus Nephritis (US)*

---

## Current Events in Nephrology

### SPECIAL TOPIX

- *Lupus Nephritis (US)*
- *Lupus Nephritis (US)*
- *Business of Nephrology*
- *Feedback from ASN Kidney Week 2023 (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices – A Cross Specialty Analysis (US) 2023*

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Generalized Myasthenia Gravis

### MARKET DYNAMIX

- *Generalized Myasthenia Gravis (US)*
- *Generalized Myasthenia Gravis (EU5)*

### LAUNCH DYNAMIX

- *SC Biologics in Generalized Myasthenia Gravis (US)*
- *Zilbrysq (UCB) in Generalized Myasthenia Gravis (US)*
- *Rozanolixizumab (UCB) in Generalized Myasthenia Gravis (US)\**
- *SC Efgartigimod alfa (Argenx) in Generalized Myasthenia Gravis (US)\**

### REALWORLD DYNAMIX

- *Generalized Myasthenia Gravis (US)*
- 

## Migraine

### REALTIME DYNAMIX

- *Migraine (US)*
- *Migraine - PCP Perspective (US)*

### LAUNCH DYNAMIX

- *Qulipta (Allergan/AbbVie) for Migraine Prevention (US)*
  - *Trudhesa (Impel) in Acute Migraine (US)*
  - *Zavzpret (Pfizer) in Acute Migraine (US)\**
- 

## Multiple Sclerosis

### REALTIME DYNAMIX

- *Multiple Sclerosis (US)*
- *Multiple Sclerosis (Canada)*

### LAUNCH DYNAMIX

- *Briumvi (TG Therapeutics) in Relapsing Multiple Sclerosis (US)*

### REALWORLD DYNAMIX

- *DMT New Starts in Multiple Sclerosis (US)*

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Emerging Neurology

### MARKET DYNAMIX

- *Amyotrophic Lateral Sclerosis (US)*
- *Alzheimer's Disease (US)*
- *Huntington's Disease (US)*
- *Parkinson's Disease (US)*
- *Sleep Disorders (US)*

### LAUNCH DYNAMIX

- *Relyvrio (Amylyx) in Amyotrophic Lateral Sclerosis (US)*
- *Donanemab (Eli Lilly) in Alzheimer's Disease (US)\**
- *Leqembi (Eisai/Biogen) in Alzheimer's Disease (US)\**
- *Ultomiris (Alexion) in Neuromyelitis Optica Spectrum Disorder (US)\**

### SPECIAL TOPIX

- *Accelerated Approvals in Early Alzheimer's Disease - Leqembi (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)*

*\*Pending approvals and launch*

*Note: Services may change due to factors such as FDA approval status and other market events*



## Neovascular Age-Related Macular Degeneration

### REALTIME DYNAMIX

- *Neovascular Age-Related Macular Degeneration (US)*

### LAUNCH DYNAMIX

- *Vabysmo (Roche/Genentech) in Neovascular Age-Related Macular Degeneration (US)*
- *Byooviz and Cimerli (Biogen/ Coherus) in Neovascular Age-Related Macular Degeneration (US)<sup>†</sup>*
- *Eylea HD in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy*
- *ONS-5010 in Neovascular Age-Related Macular Degeneration (US) \**

### REALWORLD DYNAMIX

- *Biologic New Starts in Neovascular Age-Related Macular Degeneration (US)*
  - *Biologic Treatment Switching in Neovascular Age-Related Macular Degeneration (US)*
- 

## Diabetic Macular Edema

### REALTIME DYNAMIX

- *Diabetic Macular Edema (US)*

### LAUNCH DYNAMIX

- *Vabysmo (Roche/Genentech) in Diabetic Macular Edema (US)*
- *Cimerli (Coherus) in Neovascular Age-Related Macular Degeneration (US)<sup>†</sup>*
- *8mg aflibercept in Diabetic Macular Edema (Regeneron) (US)\**

### REALWORLD DYNAMIX

- *Biologic Switches in Diabetic Macular Edema (US)*

\*Pending approvals and launch

<sup>†</sup> Monthly pulse only

Note: Services may change due to factors such as FDA approval status and other market events



## Diabetic Retinopathy

### REALWORLD DYNAMIX

- *Biologic New Starts in Diabetic Retinopathy (US)*

### SPECIAL TOPIX

- *Diabetic Retinopathy (US)*
- 

## Emerging Ophthalmology

### MARKET DYNAMIX

- *Geographic Atrophy (US)*

### LAUNCH DYNAMIX

- *Syfovre in Geographic Atrophy (US)*
- *Launch Dynamix: Avacincaptad pegol (Iveric Bio) in Geographic Atrophy (US)\**

### SPECIAL TOPIX

- *Impact of Inflation and COVID-19 on Ophthalmology Practices - (US) 2023*

*\*Pending approvals and launch*

*Note: Services may change due to factors such as FDA approval status and other market events*



## Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

### REALTIME DYNAMIX

- *Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (US)*
- *Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (EU5)*

### LAUNCH DYNAMIX

- *Rinvoq (AbbVie) in Ankylosing Spondylitis (US)*
- *Bimzelx (UCB) in Ankylosing Spondylitis (US)\**
- *Bimzelx (UCB) in Non-Radiographic Axial Spondyloarthritis (US)\**

---

## Psoriatic Arthritis

### REALTIME DYNAMIX

- *Psoriatic Arthritis (US)*
- *Psoriatic Arthritis (EU)*

### LAUNCH DYNAMIX

- *Rinvoq (AbbVie) in Psoriatic Arthritis (US)*
- *Skyrizi (AbbVie) in Psoriatic Arthritis (US)*
- *Bimzelx (UCB) in Psoriatic Arthritis (US)\**

### REALWORLD DYNAMIX

- *Triggers and Drivers in Psoriatic Arthritis (US)*

---

## Rheumatoid Arthritis

### REALTIME DYNAMIX

- *Rheumatoid Arthritis (US)*

### LAUNCH DYNAMIX

- *Artelgia (R-Pharm) in Rheumatoid Arthritis (US)\**

### REALWORLD DYNAMIX

- *Biologic/Small Molecule Switching in Rheumatoid Arthritis (US)*

\*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



## Lupus

### REALTIME DYNAMIX

- *Lupus Nephritis (US)*
- *Systemic Lupus Erythematosus (US)*
- *Systemic Lupus Erythematosus (EU5)*

### LAUNCH DYNAMIX

- *Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US)*
- *Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US) Compendium*

### REALWORLD DYNAMIX

- *Lupus Nephritis (US)*
- *Moderate to Severe Systemic Lupus Erythematosus (US)*
- *Moderate to Severe Systemic Lupus Erythematosus (EU5)*

### MARKET DYNAMIX

- *Cutaneous Lupus Erythematosus (US)*

### SPECIAL TOPIX

- *Patient Dynamics in Systemic Lupus Erythematosus (US)*

---

## Emerging Rheumatology

### MARKET DYNAMIX

- *Giant Cell Arteritis (US)*
- *Polymyalgia Rheumatica (US)*
- *Sjögren's Syndrome (US)*
- *ANCA-Associated Vasculitis (US)*

### LAUNCH DYNAMIX

- *Kevzara (Sanofi/Regeneron) in Polymyalgia Rheumatica (US)*

### REALWORLD DYNAMIX

- *ANCA-Associated Vasculitis (US)*

### SPECIAL TOPIX

- *Biosimilars Today and Tomorrow – Rheumatology (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices – A Cross Specialty Analysis (US)*

## About Spherix Global Insights

Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company's unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers.

A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.

To learn more about Spherix Global Insights, visit [spherixglobalinsights.com](http://spherixglobalinsights.com)

For more information and pricing on our services, contact us at 484.879.4284 or [info@spherixglobalinsights.com](mailto:info@spherixglobalinsights.com)  
Visit our website at [www.spherixglobalinsights.com](http://www.spherixglobalinsights.com)

**SPHERIX**  
GLOBAL INSIGHTS